Although shorter follow-up data and small numbers of patients limited analysis in some cases, survival was also markedly decreased in patients with MAPK6 overexpression above the 75th percentile in several specific cancer types in the TCGA dataset, including lung adenocarcinoma (LUAD), mesothelioma (MESO), and uveal melanoma (UVM). The gene discussed is MAPK6; the disease is mesothelioma.